RxDoctor Payments Data

Charles Snyder, MD

Gastroenterology · Cherry Hill, NJNPI 1760724504

Payments from drug & device makers

$12,762in general payments, 2019–2025

Across 119 payments — averaging $107.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$5K
  • Olympus Corporation$5K
  • Mahana Therapeutics, Inc.$700
  • AbbVie$273
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$270
  • Takeda Pharmaceuticals U.S.A., Inc.$245
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$4,93039%
  • Speaking & faculty fees$5,59544%
  • Travel & lodging$961%
  • Food & beverage$2,14017%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,762 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$81,621
Medicare patients
265
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab34$914,381
InflectraInfliximab-Dyyb13$50,275
LinzessLinaclotide25$12,991
Dexlansoprazole DrDexlansoprazole11$3,764
Omeprazole167$2,204
Lansoprazole17$1,577
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,499
Sucralfate25$1,034
Pantoprazole Sodium75$789
Esomeprazole Magnesium19$709
Famotidine31$484
Duloxetine Hcl15$434
Lactulose12$313
Dicyclomine Hcl13$219
Amitriptyline Hcl24$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$145$914,38134 claims
PfizerInflectra$49$50,27513 claims
AbbVieLinzess$273$12,99125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →